Neoprobe Initiates Phase III Cancer Trial
Posted on: Tuesday, 10 June 2008, 09:01 CDT
Neoprobe has initiated a multicenter Phase III study of Lymphoseek in patients with either breast cancer or melanoma.
The Phase III study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system.
David Bupp, president and CEO of Neoprobe, said: "Neoprobe is pleased to announce the initiation of its first Phase III study (NEO3-05) for Lymphoseek. At the present time, we have multiple sites initiated and by the end of this month, we expect to have more sites enrolling patients in the study than participated in the very successful Phase II clinical study of Lymphoseek.
"During July and August, additional sites will be initiated to commence patient enrollment including international sites, which will bring the total number of sites participating in the trial to approximately 20."
Source: Datamonitor
Related Articles
- Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years at Key Fracture Sites in Phase IIB Study
- Regeneron's ARCALYST(R) (Rilonacept) Reduced Incidence of Gout Flares By 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
- Alseres Expands Sites for Phase III Parkinson's Trial
- Neoprobe Presents Final Phase 2 Lymphoseek Results
- Neoprobe Announces Interim Phase 2 Lymphoseek Results
- Neoprobe Initiates Lymphoseek Phase 2 Clinical Study
- Erimos Pharmaceuticals Announces Phase I Study of EM-1421 Initiated at Three U.S. Sites
- Neoprobe Completes Regulatory Submission for Lymphoseek; Neoprobe Files Non-Clinical Response With FDA
- Neoprobe Establishes Corporate IND for Lymphoseek; Neoprobe Assumes Corporate Responsibility for Clinical Evaluation
 |
 |
User Comments (0)
RSS Feeds